Global Pneumonia Market: Industry Analysis & Outlook (2018-2025)
Pneumonia is a lung infection that causes inflammatory condition in one or both lungs. It affects small air sacs known as alveoli by filing them with fluid or pus, making a person difficult to breathe. It can be classified into community-acquired pneumonia and hospital-acquired pneumonia. Hospital acquired pneumonia can be further classified into healthcare associated pneumonia and ventilator associated pneumonia. A person suffering from pneumonia can experience problems like fever along with chills, cough with pus or phlegm, shortness of breath, pain in chest while breath in or coughing and lower than normal body temperature, rapid heartbeats, ongoing nausea or vomiting and decline in energy levels.
The U.S. is expected to be the first region to start selling pneumonia drugs in pipeline and later on, penetration of pneumonia drugs would occur in Europe. The U.S. and Europe have high prevalence of severe forms of multiple drug resistance (MDR) organism which would result into a high demand for pneumonia drugs in future.
The global pneumonia market is expected to grow in future with growing ageing population, increasing pharmaceutical R&D spending, increasing healthcare expenditure, accelerating economic growth, growing children population and rise in multiple drug resistance (MDR) organisms. Key trends of this market include progressing drug under pipeline, innovation in treatment options and increased preference towards combination therapy. However, there are some factors which can hinder growth of the market including stringent regulations and entry of generic drugs.
The report “Global Pneumonia Market: Industry Analysis & Outlook (2018-2025)” by Koncept Analytics provides an extensive research and detailed analysis of the present market along with future outlook. The report discusses the major growth drivers and challenges of the market, covering U.S, and Europe along with the global market. The report profiles key players of the market including Merck & Co. Inc., Allergan Plc, The Medicines Company and Nabriva Therapeutics.
The U.S. is expected to be the first region to start selling pneumonia drugs in pipeline and later on, penetration of pneumonia drugs would occur in Europe. The U.S. and Europe have high prevalence of severe forms of multiple drug resistance (MDR) organism which would result into a high demand for pneumonia drugs in future.
The global pneumonia market is expected to grow in future with growing ageing population, increasing pharmaceutical R&D spending, increasing healthcare expenditure, accelerating economic growth, growing children population and rise in multiple drug resistance (MDR) organisms. Key trends of this market include progressing drug under pipeline, innovation in treatment options and increased preference towards combination therapy. However, there are some factors which can hinder growth of the market including stringent regulations and entry of generic drugs.
The report “Global Pneumonia Market: Industry Analysis & Outlook (2018-2025)” by Koncept Analytics provides an extensive research and detailed analysis of the present market along with future outlook. The report discusses the major growth drivers and challenges of the market, covering U.S, and Europe along with the global market. The report profiles key players of the market including Merck & Co. Inc., Allergan Plc, The Medicines Company and Nabriva Therapeutics.
1. MARKET OVERVIEW
1.1 Pneumonia
1.2 Causes
1.3 Symptoms and Diagnosis
1.4 Treatment
2. GLOBAL PNEUMONIA MARKET ANALYSIS
2.1 Pneumonia Market
2.1.1 Global Lefamulin Drug Revenue Forecast
2.1.2 Global ASN100 Drug Revenue Forecast
3. REGIONAL MARKETS
3.1 The U.S.
3.1.1 The U.S. CAP Patient Population Forecast
3.1.2 The U.S. CAP Patient Population by Category
3.1.3 The U.S. CAP Outpatient Population Forecast
3.1.4 The U.S. CAP Hospital Patient Population Forecast
3.1.5 The U.S. HAP/VAP Population Forecast
3.1.6 The U.S. Lefamulin Drug Revenue Forecast by Category
3.1.7 The U.S. Lefamulin Drug Revenue Forecast by Patient Type for CAP
3.1.8 The U.S. Lefamulin Drug Revenue Forecast for HAP/VAP
3.1.9 The U.S. ASN100 Drug Revenue Forecast for VAP
3.2 Europe
3.2.1 Europe CAP Patient Population Forecast
3.2.2 Europe CAP Patient Population by Category
3.2.3 Europe CAP Hospital Patient Population by Category
3.2.4 Europe CAP Outpatient Population Forecast
3.2.5 Europe VAP Patient Population Forecast
3.2.6 Europe Lefamulin Drug Revenue Forecast by Patient Type for CAP
3.2.7 Europe ASN100 Drug Revenue Forecast for VAP
4. MARKET DYNAMICS
4.1 Growth Drivers
4.1.1 Growing Ageing Population
4.1.2 Increasing Pharmaceutical R&D Spending
4.1.3 Increasing Healthcare Expenditure
4.1.4 Accelerating Economic Growth
4.1.5 Growing Children Population
4.1.6 Rise in Multiple Drug Resistance (MDR) Organisms
4.2 Key Trends & Developments
4.2.1 Progressing Drugs Under Pipeline
4.2.2 Innovation in Treatment Methods
4.2.3 Increased Preference Towards Combination Therapy
4.3 Challenges
4.3.1 Stringent Regulations
4.3.2 Entry of Generic Drugs
5. COMPETITIVE LANDSCAPE
5.1 Global Market
5.1.1 Revenue Comparison of Key Players
5.1.2 Market Cap Comparison of Key Players
6. COMPANY PROFILES
6.1 Nabriva Therapeutics
6.1.1 Business Overview
6.1.2 Financial Overview
6.1.3 Business Strategies
6.2 Merck & Co., Inc.
6.2.1 Business Overview
6.2.2 Financial Overview
6.2.3 Business Strategies
6.3 Allergan Plc
6.3.1 Business Overview
6.3.2 Financial Overview
6.3.3 Business Strategies
6.4 The Medicines Company
6.4.1 Business Overview
6.4.2 Financial Overview
6.4.3 Business Strategies
1.1 Pneumonia
1.2 Causes
1.3 Symptoms and Diagnosis
1.4 Treatment
2. GLOBAL PNEUMONIA MARKET ANALYSIS
2.1 Pneumonia Market
2.1.1 Global Lefamulin Drug Revenue Forecast
2.1.2 Global ASN100 Drug Revenue Forecast
3. REGIONAL MARKETS
3.1 The U.S.
3.1.1 The U.S. CAP Patient Population Forecast
3.1.2 The U.S. CAP Patient Population by Category
3.1.3 The U.S. CAP Outpatient Population Forecast
3.1.4 The U.S. CAP Hospital Patient Population Forecast
3.1.5 The U.S. HAP/VAP Population Forecast
3.1.6 The U.S. Lefamulin Drug Revenue Forecast by Category
3.1.7 The U.S. Lefamulin Drug Revenue Forecast by Patient Type for CAP
3.1.8 The U.S. Lefamulin Drug Revenue Forecast for HAP/VAP
3.1.9 The U.S. ASN100 Drug Revenue Forecast for VAP
3.2 Europe
3.2.1 Europe CAP Patient Population Forecast
3.2.2 Europe CAP Patient Population by Category
3.2.3 Europe CAP Hospital Patient Population by Category
3.2.4 Europe CAP Outpatient Population Forecast
3.2.5 Europe VAP Patient Population Forecast
3.2.6 Europe Lefamulin Drug Revenue Forecast by Patient Type for CAP
3.2.7 Europe ASN100 Drug Revenue Forecast for VAP
4. MARKET DYNAMICS
4.1 Growth Drivers
4.1.1 Growing Ageing Population
4.1.2 Increasing Pharmaceutical R&D Spending
4.1.3 Increasing Healthcare Expenditure
4.1.4 Accelerating Economic Growth
4.1.5 Growing Children Population
4.1.6 Rise in Multiple Drug Resistance (MDR) Organisms
4.2 Key Trends & Developments
4.2.1 Progressing Drugs Under Pipeline
4.2.2 Innovation in Treatment Methods
4.2.3 Increased Preference Towards Combination Therapy
4.3 Challenges
4.3.1 Stringent Regulations
4.3.2 Entry of Generic Drugs
5. COMPETITIVE LANDSCAPE
5.1 Global Market
5.1.1 Revenue Comparison of Key Players
5.1.2 Market Cap Comparison of Key Players
6. COMPANY PROFILES
6.1 Nabriva Therapeutics
6.1.1 Business Overview
6.1.2 Financial Overview
6.1.3 Business Strategies
6.2 Merck & Co., Inc.
6.2.1 Business Overview
6.2.2 Financial Overview
6.2.3 Business Strategies
6.3 Allergan Plc
6.3.1 Business Overview
6.3.2 Financial Overview
6.3.3 Business Strategies
6.4 The Medicines Company
6.4.1 Business Overview
6.4.2 Financial Overview
6.4.3 Business Strategies
LIST OF CHARTS
Classification of Pneumonia
Global Lefamulin Drug Revenue Forecast (2019-2025)
Global ASN100 Drug Revenue Forecast (2021-2025)
The U.S. CAP Patient Population Forecast (2017-2022)
The U.S. CAP Patient Population by Category (2017)
The U.S. CAP Outpatient Population Forecast (2017-2022)
The U.S. CAP Hospital Patient Population Forecast (2017-2022)
The U.S. HAP/VAP Population Forecast (2022-2025)
The U.S. Lefamulin Drug Revenue Forecast by Category (2019-2025)
The U.S. Lefamulin Drug Revenue Forecast By Patient Type for CAP (2019-2025)
The U.S. Lefamulin Drug Revenue Forecast for HAP/VAP (2022-2025)
The U.S. ASN100 Drug Revenue Forecast for VAP (2021-2025)
Europe CAP Patient Population Forecast (2017-2022)
Europe CAP Patient Population by Category (2017)
Europe CAP Hospital Patient Population Forecast (2017-2022)
Europe CAP Outpatient Population Forecast (2017-2022)
Europe VAP Patient Population Forecast (2021-2025)
Europe Lefamulin Drug Revenue Forecast by Patient Type for CAP (2021-2025)
Europe ASN100 Drug Revenue Forecast for VAP (2022-2025)
Global Ageing Population (2012-2017)
Global Pharmaceutical R&D Spending (2013-2017)
Global Healthcare Expenditure (2012-2017)
Global GDP Per Capita (2012-2017)
Global Children Population (2012-2017)
Global Pneumonia Market Key Players - Market Cap Comparison (2016)
Nabriva Therapeutics Net Revenue and Net Income (Loss) (2013-2016)
Nabriva Therapeutics Research and Development Expenditure (2014-2016)
Merck & Co., Inc. Revenue Share by Segments (2016)
Merck & Co., Inc. Net Revenue and Net Income (2012-2016)
Merck & Co. Research and Development Expenditure (2014-2016)
Allergan Plc Revenue Share by Segments (2016)
Allergan Plc Net Revenue and Net Income (2012-2016)
Allergan Plc Research and Development Expenditure (2014-2016)
The Medicines Company Revenue Share by Products (2016)
The Medicines Company Net Revenue and Net Income (Loss) (2012-2016)
The Medicines Company Research and Development Expenditure (2014-2016)
Classification of Pneumonia
Global Lefamulin Drug Revenue Forecast (2019-2025)
Global ASN100 Drug Revenue Forecast (2021-2025)
The U.S. CAP Patient Population Forecast (2017-2022)
The U.S. CAP Patient Population by Category (2017)
The U.S. CAP Outpatient Population Forecast (2017-2022)
The U.S. CAP Hospital Patient Population Forecast (2017-2022)
The U.S. HAP/VAP Population Forecast (2022-2025)
The U.S. Lefamulin Drug Revenue Forecast by Category (2019-2025)
The U.S. Lefamulin Drug Revenue Forecast By Patient Type for CAP (2019-2025)
The U.S. Lefamulin Drug Revenue Forecast for HAP/VAP (2022-2025)
The U.S. ASN100 Drug Revenue Forecast for VAP (2021-2025)
Europe CAP Patient Population Forecast (2017-2022)
Europe CAP Patient Population by Category (2017)
Europe CAP Hospital Patient Population Forecast (2017-2022)
Europe CAP Outpatient Population Forecast (2017-2022)
Europe VAP Patient Population Forecast (2021-2025)
Europe Lefamulin Drug Revenue Forecast by Patient Type for CAP (2021-2025)
Europe ASN100 Drug Revenue Forecast for VAP (2022-2025)
Global Ageing Population (2012-2017)
Global Pharmaceutical R&D Spending (2013-2017)
Global Healthcare Expenditure (2012-2017)
Global GDP Per Capita (2012-2017)
Global Children Population (2012-2017)
Global Pneumonia Market Key Players - Market Cap Comparison (2016)
Nabriva Therapeutics Net Revenue and Net Income (Loss) (2013-2016)
Nabriva Therapeutics Research and Development Expenditure (2014-2016)
Merck & Co., Inc. Revenue Share by Segments (2016)
Merck & Co., Inc. Net Revenue and Net Income (2012-2016)
Merck & Co. Research and Development Expenditure (2014-2016)
Allergan Plc Revenue Share by Segments (2016)
Allergan Plc Net Revenue and Net Income (2012-2016)
Allergan Plc Research and Development Expenditure (2014-2016)
The Medicines Company Revenue Share by Products (2016)
The Medicines Company Net Revenue and Net Income (Loss) (2012-2016)
The Medicines Company Research and Development Expenditure (2014-2016)
LIST OF TABLES
Drugs under Development for Pneumonia (2017)
Global Pneumonia Market Key Players - Revenue Comparison (2016)
Allergan Plc Agreements (2016)
Drugs under Development for Pneumonia (2017)
Global Pneumonia Market Key Players - Revenue Comparison (2016)
Allergan Plc Agreements (2016)
